
PRESS RELEASE

iX BIOPHARMA ANNOUNCES DEVELOPMENT OF SUPPLEMENT FOR JET LAG

- ✓ **First supplement in the Group's product pipeline**
- ✓ **Lower cost of development and shorter time-to-market compared to pharmaceutical products**

Singapore, 17 August 2016 – Homegrown specialty pharmaceutical company **iX Biopharma Ltd.** ("iX Biopharma" or, together with its subsidiaries, "the Group") has completed pre-clinical development for **WafeRest**, a sublingual melatonin wafer supplement aimed to alleviate jet lag and improve sleep quality.

Melatonin is a hormone produced in the brain that regulates the circadian rhythm (sleep-wake cycle) and people's ability to sleep. Research has shown that melatonin has a low absolute bioavailability either due to poor oral absorption, large first-pass metabolism, or a combination of both. The use of iX Biopharma's **WaferiX** sublingual technology potentially allows for the improvement of its bioavailability as the delivery of the drug bypasses the first-pass metabolism, and hence offers a more rapid and predictable dosage of melatonin.

With millions of business and leisure travellers today taking flights that cross multiple time zones, flight dysrhythmia, or jet lag, has become a common phenomenon as these travellers experience a temporary misalignment between the body's circadian clock and external time. The symptoms of jet lag, which include daytime fatigue, impaired alertness, night-time insomnia and impaired cognitive skills, can be addressed by melatonin, which regulates disturbed circadian rhythms and promotes sleep in jet lag and other circadian rhythm sleep disorders.

iX Biopharma has completed pre-clinical development of **WafeRest**, and commenced batch stability testing in FY2016. Upon completion of stability testing, the Group will file the product for export listing with the Australian Therapeutic Goods Administration for sale in the region. As a supplement, **WafeRest** does not require an additional clinical study (including in-human

study) for registration. This means that the development cost for **WafeRest** is substantially lower and time-to-market is shorter compared to pharmaceutical products.

WafeRest is the first supplement in the Group's pipeline of products, which also includes **BnoX** and **Wafermine**, a sublingual buprenorphine and a sublingual ketamine respectively, for acute and severe pain management; and **PheoniX**, a sublingual sildenafil for erectile dysfunction.

About iX Biopharma Ltd

iX Biopharma Ltd is a Singapore public-listed specialty pharmaceutical company, with manufacturing and laboratory testing facilities in Australia. The Group is focused on the development and commercialisation of innovative therapies for improving the quality of life of those suffering from pain and other health issues. The Company leverages its patented sublingual drug delivery technology, **WaferiX**, to develop proprietary products that incorporate pharmacologically active compounds that have been approved by the United States Food and Drug Administration. Its portfolio of products under development includes **Wafermine** and **BnoX** for pain management, **PheoniX** for erectile dysfunction, and **WafeRest** for improved sleep quality.

Contact for media:

Ms Alvina Tan

DID: +65 6221 2123

H/P: +65 9787 7267

Email: alvina.tan@arkadvisors.com.sg**Ms Karin Lai**

DID: +65 6221 0081

H/P: +65 9837 8136

Email: karin.lai@arkadvisors.com.sg

This document has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, CIMB Bank Berhad, Singapore Branch, for compliance with the relevant rules of the SGX-ST. CIMB Bank Berhad, Singapore Branch, has not independently verified the contents of this announcement. This document has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr Tony Toh, Director, Investment Banking, CIMB Bank Berhad, Singapore Branch. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.